StockData
Stoke Therapeutics, Inc. logo

Stoke Therapeutics, Inc. (STOK) stock

STOKNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 6/30173% above fair value
$26.69+0.28 (+1.06%)

Close on Nov 18, 2026Market cap $1.72BP/E –Yield –

Stoke Therapeutics revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Stoke Therapeutics's revenue for the twelve months ending Jun 30, 2026 was $27.59M, down 86.2% year over year. For fiscal 2025 it was $184.42M, up 404.5% from the year before.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$184.42M+404.5%
FY2024Dec 31, 2024$36.56M+316.3%
FY2023Dec 31, 2023$8.78M-29.2%
FY2022Dec 31, 2022$12.41M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$9.33M-32.5%
Q1 FY2026Mar 31, 2026$6.23M-96.1%
Q4 FY2025Dec 31, 2025$1.40M-93.8%
Q3 FY2025Sep 30, 2025$10.63M+117.2%
Q2 FY2025Jun 30, 2025$13.82M+186.0%
Q1 FY2025Mar 31, 2025$158.57M+3661.1%
Q4 FY2024Dec 31, 2024$22.61M+707.1%
Q3 FY2024Sep 30, 2024$4.89M+47.9%
Q2 FY2024Jun 30, 2024$4.83M–
Q1 FY2024Mar 31, 2024$4.22M-18.2%
Q4 FY2023Dec 31, 2023$2.80M-14.3%
Q3 FY2023Sep 30, 2023$3.31M+13.9%
Q2 FY2023Jun 30, 2023-$2.48M-176.8%
Q1 FY2023Mar 31, 2023$5.15M+71.7%
Q4 FY2022Dec 31, 2022$3.27M–
Q3 FY2022Sep 30, 2022$2.91M–
Q2 FY2022Jun 30, 2022$3.23M–
Q1 FY2022Mar 31, 2022$3.00M–

More Stoke Therapeutics figures

See a number that looks wrong?